Invion

Invion Cost of Goods Sold

The Cost of Goods Sold (COGS) of Invion (IVX.AX) as of Oct 23, 2026 is 1.29 M AUD. In the previous year, Cost of Goods Sold (COGS) was 2.69 M AUD — a change of -52.05% (lower).

Cost of Goods Sold

1.29 MAUD

YoY

-52.05%

Last updated:

Cost of Goods Sold (COGS) of Invion is 2025 1.29 M AUD. Cost of Goods Sold (COGS) of Invion was 2024 2.69 M AUD. It decreases by -52.05% lower compared to the previous year.

The Invion Cost of Goods Sold history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cost of Goods Sold
Date
Cost of Goods Sold
Jan 1, 2018
370,886.00 AUD
Jan 1, 2019
2.26 M AUD
Jan 1, 2020
1.56 M AUD
Jan 1, 2021
1.52 M AUD
Jan 1, 2022
2.32 M AUD
Jan 1, 2023
2.90 M AUD
Jan 1, 2024
2.69 M AUD
Jan 1, 2025
1.29 M AUD
The Invion Cost of Goods Sold history
YEARCost of Goods SoldYoY
1.29 MAUD-52.05%
2.69 MAUD-7.15%
2.90 MAUD+24.78%
2.32 MAUD+52.85%
1.52 MAUD-2.61%
1.56 MAUD-30.86%
2.26 MAUD+508.51%
370,886.00AUD-70.21%
1.24 MAUD-5.71%
1.32 MAUD-85.36%
9.02 MAUD+294.15%
2.29 MAUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Invion Stock analysis

What does Invion do? Invion Ltd is an Australian company specializing in the development of treatment solutions for respiratory and inflammatory diseases. The company was originally founded in 2000 and is headquartered in Perth, Western Australia. It began as a company called CBio that focused on developing technology to prevent blood clot formation. In 2004, it was renamed Invion and shifted its focus to developing treatment solutions for respiratory and inflammatory diseases. Invion has acquired several pharmaceutical companies and has developed an innovative pipeline of products. The company is positioned as a biopharmaceutical company specializing in the discovery and development of treatments based on immunological research for the prevention, diagnosis, and treatment of severe respiratory and inflammatory diseases. It utilizes a combination of proprietary platform technology and internal expertise and collaborates with small and mid-sized pharmaceutical companies. Invion is divided into three main business divisions: antiviral treatment, immunomodulation, and diagnostics. In terms of products, Invion has several in development stages, including INV102 for severe asthma, INV103 for Covid-19, INV104 for lung inflammation, INV027 for COPD, and INV043 for allergic asthma. Overall, Invion aims to improve patient care and diagnosis in the respiratory and inflammatory disease space through innovative technologies. Invion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Invion stock

Cost of Goods Sold (COGS) of Invion is 1.29 M AUD in 2025.

Cost of Goods Sold (COGS) of Invion changed from 2.69 M AUD to 1.29 M AUD, representing a -52.05% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cost of Goods Sold (COGS) Invion since 2006 – with annual values, charts, and detailed analysis.

COGS represents the direct costs attributable to the production of goods sold. It includes material and labor costs directly tied to the product.

Cost of Goods Sold (COGS)'s AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Cost of Goods Sold (COGS)'s Invion historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Invion

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Invion